Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

Rhea-AI Summary

Onconova Therapeutics, Inc. (NASDAQ: ONTX) will attend the RHK Capital Disruptive Growth Conference on December 5-6, 2022, in New York City. Mark Guerin, COO and CFO, will present a corporate overview on December 6 at 11:20 a.m. ET.

Onconova focuses on developing innovative cancer treatments, including narazaciclib and rigosertib, which are currently in clinical trials. These drugs are designed to target specific cancer pathways to disrupt cell proliferation, with ongoing studies in the U.S. and China.

News Market Reaction – ONTX

+0.20%

+0.20% Session move

In the trading session that priced this news, ONTX gained 0.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Mark Guerin, Chief Operating Officer & Chief Financial Officer, will present a corporate overview at the conference on Tuesday, December 6^th at 11:20 a.m. ET.

To learn more or submit a registration request for the conference, visit http://disruptnyc.com/.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What is Onconova Therapeutics participating in on December 5-6, 2022?

Onconova Therapeutics will participate in the RHK Capital Disruptive Growth Conference in New York City.

Who will present Onconova's corporate overview at the conference?

Mark Guerin, the COO and CFO of Onconova Therapeutics, will present the corporate overview.

What time is Onconova's corporate overview presentation at the conference?

The corporate overview presentation by Onconova will be on December 6, 2022, at 11:20 a.m. ET.

What are the key products being developed by Onconova?

Onconova is developing narazaciclib and rigosertib, which target specific cancer pathways.

Where are Onconova's clinical trials currently taking place?

Onconova's clinical trials for narazaciclib and rigosertib are underway in the United States and China.